Innovative Pioneers of the Hemp Trade
Elixinol, Merges Water-Soluble Technology with THC-Free CBD in a New Range of CBD Blended Tinctures.
The role of plants in drugs and medicines
Dr Deborah Lee from Dr Fox Online Pharmacy sheds light on the role of plants in drugs and medicines in this absorbing analysis.
The use of medical cannabis in the UK
Andreas Met, COO, Compliance and Director at Halo Labs highlights how the use of medical cannabis is on the rise in the UK and could offer relief to many NHS patients.
A medical professional’s opinion on medical marijuana
Dr Charlie Easmon from Your Excellent Health Service gives a medical professional’s opinion on medical marijuana in the UK, including comment on hemp, CBD and THC.
The priorities for cannabis research
Here, Robin Emerson, Head of CSR at Brains Bioceutical charts the priorities for cannabis research.
The UK’s clinicians need training in medical cannabis – here’s why
Professor Mike Barnes, Co-Founder of Maple Tree Consultancy states that the UK’s clinicians need training in medical cannabis and explains precisely why this should be.
Can the UK’s post-COVID-19 economy benefit from a booming medical cannabis industry?
Hannah Deacon, Co-Founder of Maple Tree Consultancy and Campaigner ponders if the UK’s post-COVID-19 economy can benefit from a booming medical cannabis industry.
EU Pharma Strategy: COVID-19 shows the need for diverse supply chains
Rex Clements, CEO at Centrient Pharmaceuticals, discusses how the upcoming EU Pharma Strategy can prevent shortages and strengthen Europe’s manufacturing base, especially for antibiotics.
Research finds cannabis could reduce OCD symptoms by 50%
OCD symptoms could be eased by atleast half in the short-term, according to a new study published in the Journal of Affective Disorders.
CBG: The mother of all Cannabinoids with broad antibacterial activity
Dr. Christian Löfke, researcher and product developer at BioBloom in Austria explains CBG (cannabigerol), a “new” cannabinoid with vast potential in cannabis research.
Savage Cabbage: Where did it begin?
In early 2016, I had reached a point in life where I needed to make a life-changing decision: Read the Savage Cabbage journey on OAG.
Ilesol Pharmaceuticals: First European cannabinoid à la carte company
Here, Ilesol Pharmaceuticals discuss how they became the first European cannabinoid company to unlock this sector of the market.
EUMCA: Medical cannabis and research collaboration after Brexit
Here, we talk to Professor Trevor Jones at the European Medical Cannabis Association (EUMCA) about storing CBD, clinical trials post-Brexit and the UK-US trade deal.
CBD: Narcotic substance or a novel food product?
CBD is at the forefront of pharmacology. So why has the European Commission changed its recommended status to “Narcotic”? Read on to find out more.
Ensuring regulatory compliance for Medical Cannabis
Here, Evolve Ltd’s Managing Director, Christopher Busuttil Delbridge, takes us progressively deeper into what it takes to ensure regulatory compliance for Medical Cannabis.
COVID is shifting the conversation about the medical application of CBD
Hannah Deacon, co-founder of Maple Tree Consultancy, explores how COVID is elevating and shaping the medical application of CBD.
A comprehensive guide to CBD in the UK
Here, Professor Mike Barnes discusses and answers some key questions about the world of CBD in the UK.
Antimicrobial resistance: The next big pandemic?
Josep Figueras and Anna Sagan from the European Observatory on Health Systems and Policies focus here on antimicrobial resistance and ponder whether or not this could be the next big pandemic.
Ensuring a high and reproducible quality of medicinal cannabis
Renata Mala, PharmD, Chairman of Purely Plant GmbH, underlines the importance of ensuring high and reproducible quality when it comes to medicinal cannabis.
MHL Series B equity financing and global CPG partnerships
Here, we learn how Mile High Labs, a leading processor of hemp-derived cannabinoids, have raised Series B equity financing and are preparing for global CPG partnerships.
